Search | VHL Search Portal

1.

The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.

Feng, Joy Y; Du Pont, Venice; Babusis, Darius; Gordon, Calvin J; Tchesnokov, Egor P; Perry, Jason K; Duong, Vincent; Vijjapurapu, Arya; Zhao, Xiaofeng; Chan, Julie; Cohen, Cal; Juneja, Kavita; Cihlar, Tomas; Götte, Matthias; Bilello, John P.

Molecules ; 27(13)2022 Jun 30.

Article in English | MEDLINE | ID: mdl-35807457

2.

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.

Erlandson, Kristine M; Carter, Christoph C; Melbourne, Kathleen; Brown, Todd T; Cohen, Cal; Das, Moupali; Esser, Stefan; Huang, Hailin; Koethe, John R; Martin, Hal; McComsey, Grace A; Orkin, Chloe; Post, Frank A; Rockstroh, Jürgen K; Sax, Paul E; Stellbrink, Hans-Jürgen; Waters, Laura; Wei, Xuelian; Lake, Jordan E.

Clin Infect Dis ; 73(8): 1440-1451, 2021 10 20.

Article in English | MEDLINE | ID: mdl-33987636

3.

Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.

Mocroft, Amanda; Pelchen-Matthews, Annegret; Hoy, Jennifer; Llibre, Josep M; Neesgaard, Bastian; Jaschinski, Nadine; Domingo, Pere; Rasmussen, Line Dahlerup; Günthard, Huldrych F; Surial, Bernard; Öllinger, Angela; Knappik, Michael; de Wit, Stephane; Wit, Ferdinand; Mussini, Cristina; Vehreschild, Joerg; Monforte, Antonella D'Arminio; Sonnerborg, Anders; Castagna, Antonella; Anne, Alain Volny; Vannappagari, Vani; Cohen, Cal; Greaves, Wayne; Wasmuth, Jan C; Spagnuolo, Vincenzo; Ryom, Lene.

AIDS ; 38(4): 497-508, 2024 Mar 15.

Article in English | MEDLINE | ID: mdl-38079588

4.

Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.

Byonanebye, Dathan M; Polizzotto, Mark N; Maltez, Fernando; Rauch, Andri; Grabmeier-Pfistershammer, Katharina; Wit, Ferdinand; De Wit, Stéphane; Castagna, Antonella; d'Arminio Monforte, Antonella; Mussini, Cristina; Wasmuth, Jan-Christian; Fontas, Eric; Abela, Irene; Sarcletti, Mario; Bansi-Matharu, Loveleen; Jaschinski, Nadine; Peters, Lars; Hosein, Sean R; Vannappagari, Vani; Cohen, Cal; Bissio, Emiliano; Mocroft, Amanda; Law, Matthew; Ryom, Lene; Petoumenos, Kathy.

Lancet HIV ; 11(5): e321-e332, 2024 May.

Article in English | MEDLINE | ID: mdl-38621392

5.

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression.

Castillo-Mancilla, Jose R; Morrow, Mary; Hunt, Peter W; Schnittman, Samuel R; Phillips, Andrew N; Baker, Jason V; Haberer, Jessica E; Janeiro, Maria Joao; Aragao, Filipa; Cohen, Cal; Musinguzi, Nicholas; Brown, Todd T; Cavassini, Matthias; Glass, Tracy R; Serrano-Villar, Sergio; Mawhinney, Samantha; Siedner, Mark.

Open Forum Infect Dis ; 10(5): ofad230, 2023 May.

Article in English | MEDLINE | ID: mdl-37213424

6.

Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.

Hill, Andrew; Grossman, Howard; Cohen, Cal; Nadler, Jeff; Peeters, Monika.

HIV Clin Trials ; 8(2): 68-76, 2007.

Article in English | MEDLINE | ID: mdl-17507322

7.

Stalemate--but not checkmate. An expert takes on the challenges. Interview by Jeff Berry.

Cohen, Cal.

Posit Aware ; 21(2): 56-8, 2010.

Article in English | MEDLINE | ID: mdl-20524352

8.

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.

Porter, Danielle P; Daeumer, Martin; Thielen, Alexander; Chang, Silvia; Martin, Ross; Cohen, Cal; Miller, Michael D; White, Kirsten L.

Viruses ; 7(12): 6360-70, 2015 Dec 07.

Article in English | MEDLINE | ID: mdl-26690199

9.

Treatment interruption; advanced HIV; new ideas: Dr. Cal Cohen interview on retrovirus conference (part 2 or 2). Interview by John S. James.

Cohen, Cal.

AIDS Treat News ; (390): 2-5, 2003 Apr 04.

Article in English | MEDLINE | ID: mdl-12739473

10.

Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James.

Cohen, Cal.

AIDS Treat News ; (389): 2-6, 2003 Mar 14.

Article in English | MEDLINE | ID: mdl-12712936

11.

New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D. Interview by John S. James.

Cohen, Cal.

AIDS Treat News ; (405): 3-6, 2004 Sep 24.

Article in English | MEDLINE | ID: mdl-15595150

12.

Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. Interview by John S. James.

Cohen, Cal.

AIDS Treat News ; (407-408): 2-4, 2004.

Article in English | MEDLINE | ID: mdl-15717379

13.

Antiretroviral treatment update from the 17th International AIDS Conference.

Boyle, Brian; Cohen, Cal; DeJesus, Edwin; Elion, Richard; Frank, Ian; Moyle, Graeme; Sax, Paul.

AIDS Read ; 18(11): 570-9, 2008 Nov.

Article in English | MEDLINE | ID: mdl-19062402

14.

Durable suppression possible with FOTO treatment schedule in subjects on nevirapine-based regimens.

Cohen, Cal; Colson, Amy.

HIV Clin Trials ; 8(4): 256, 2007.

Article in English | MEDLINE | ID: mdl-17720667

15.

Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.

Youle, Mike; Cohen, Cal; Katlama, Christine; Kuritzkes, Dan; Walmsley, Sharon.

Lancet ; 364(9439): 1036-7, 2004.

Article in English | MEDLINE | ID: mdl-15380959

16.

HAART at 10: an interview with Cal Cohen.

Cohen, Cal.

Res Initiat Treat Action ; 11(1): 49-51, 2005.

Article in English | MEDLINE | ID: mdl-16208821

17.

New fixed dose once-a-day combinations. Interview by John S. James.

Cohen, Cal.

IAPAC Mon ; 10(11): 414-5, 432, 2004 Nov.

Article in English | MEDLINE | ID: mdl-15744891

18.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox, Zoe; Phillips, Andrew; Cohen, Cal; Neuhaus, Jacquie; Baxter, John; Emery, Sean; Hirschel, Bernard; Hullsiek, Kathy Huppler; Stephan, Christoph; Lundgren, Jens.

AIDS ; 22(17): 2279-89, 2008 Nov 12.

Article in English | MEDLINE | ID: mdl-18981767

19.

Issues in the design of trials comparing management strategies for heavily pretreated patients.

Phillips, Andrew N; Cohen, Cal; Lundgren, Jens D.

Curr Opin HIV AIDS ; 1(6): 476-81, 2006 Nov.

Article in English | MEDLINE | ID: mdl-19372849

20.

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.

Tebas, Pablo; Henry, Keith; Mondy, Kristin; Deeks, Steven; Valdez, Herman; Cohen, Cal; Powderly, William G.

J Infect Dis ; 186(6): 851-4, 2002 Sep 15.

Article in English | MEDLINE | ID: mdl-12198623

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export:

The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.

Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression.

Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.

Stalemate--but not checkmate. An expert takes on the challenges. Interview by Jeff Berry.

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.

Treatment interruption; advanced HIV; new ideas: Dr. Cal Cohen interview on retrovirus conference (part 2 or 2). Interview by John S. James.

Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James.

New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D. Interview by John S. James.

Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. Interview by John S. James.

Antiretroviral treatment update from the 17th International AIDS Conference.

Durable suppression possible with FOTO treatment schedule in subjects on nevirapine-based regimens.

Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.

HAART at 10: an interview with Cal Cohen.

New fixed dose once-a-day combinations. Interview by John S. James.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Issues in the design of trials comparing management strategies for heavily pretreated patients.

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.